Get started
Author

Dominik B. Dahl

Observed names: D Dahl, D. Dahl, D.B. Dahl, DOMINIK DAHL, Dominik Dahl, DominikB. Dahl
OpenAlex ID: A5109925049
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
2022 · Dominik Dahl, Yukiko Onishi, et al. · JAMA · 639
PDF
Effects of Intravenous and Dietary Lipid Challenge on Intramyocellular Lipid Content and the Relation With Insulin Sensitivity in Humans
2001 · Oliver P. Bachmann, Dominik B. Dahl, et al. · Diabetes · 375
PDF
Intramyocellular Lipids: Anthropometric Determinants and Relationships with Maximal Aerobic Capacity and Insulin Sensitivity
2003 · Claus Thamer, Jürgen Machann, et al. · The Journal of Clinical Endocrinology & Metabolism · 232
Fast elevation of the intramyocellular lipid content in the presence of circulating free fatty acids and hyperinsulinemia: A dynamic1H-MRS study
2001 · K. Brechtel, D.B. Dahl, et al. · Magnetic Resonance in Medicine · 107
Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26‐week PRONTO‐T1D study
2020 · Leslie Klaff, Dachuang Cao, et al. · Diabetes Obesity and Metabolism · 93
Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine ( L antus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study
2015 · T. C. Blevins, D. Dahl, et al. · Diabetes Obesity and Metabolism · 81
PDF
Lipid content in the musculature of the lower leg assessed by fat selective MRI: Intra‐ and interindividual differences and correlation with anthropometric and metabolic data
2003 · Jürgen Machann, Oliver P. Bachmann, et al. · Journal of Magnetic Resonance Imaging · 72
PDF
Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment
2024 · Carol Wysham, Harpreet S. Bajaj, et al. · New England Journal of Medicine · 67
Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes
2023 · Christof M. Kazda, Juliana M. Bue-Valleskey, et al. · Diabetes Care · 58
PDF
Relationship between Serum Adiponectin Concentration and Intramyocellular Lipid Stores in Humans
2002 · C. Thamer, J. Machann, et al. · Hormone and Metabolic Research · 56
Introduction of biosimilar insulins in Europe
2017 · M. Davies, D. Dahl, et al. · Diabetic Medicine · 42
PDF
Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial
2025 · Thomas Blevins, Dominik Dahl, et al. · The Lancet · 34
Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
2016 · I. Hadjiyianni, D. Dahl, et al. · Diabetes Obesity and Metabolism · 31
PDF
Effect of Glimepiride on Insulin-Stimulated Glycogen Synthesis in Cultured Human Skeletal Muscle Cells
2002 · Axel Haupt, Christiana Kausch, et al. · Diabetes Care · 30
PDF
A 96‐week, double‐blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults
2022 · Yuan‐Di Halvorsen, John Paul Lock, et al. · Diabetes Obesity and Metabolism · 29
PDF
Increased insulin clearance in peroxisome proliferator-activated receptor γ2 Pro12Ala
2003 · Otto Tschritter, Andreas Fritsche, et al. · Metabolism · 28
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis
2025 · Peter Rossing, George Bakris, et al. · Diabetes Care · 25
PDF
80-LB: Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Is Effective and Safe When Added to Basal Insulin for Treatment of Type 2 Diabetes (SURPASS-5)
2021 · DOMINIK DAHL, YUKIKO ONISHI, et al. · Diabetes · 15
Long-Term Efficacy and Safety of Ultra Rapid Lispro (URLi) in Adults with Type 1 Diabetes: The PRONTO-T1D Extension
2021 · Juliana Bue-Valleskey, Leslie Klaff, et al. · Diabetes Therapy · 14
PDF
144-OR: Ultra Rapid Lispro (URLi) Improves Postprandial Glucose (PPG) Control vs. Humalog (Lispro) in T1D: PRONTO-T1D Study
2019 · LESLIE J. KLAFF, DACHUANG CAO, et al. · Diabetes · 8
Orlistat (Xenical®) improves insulin sensitivity (IS) in obese intentionally weight maintaining subjects
2000 · OliverP. Bachmann, DominikB. Dahl, et al. · Diabetes Research and Clinical Practice · 7
Verminderte Insulinwirkung bei subklinischer Leberzellverfettung
2004 · C Thamer, J Machann, et al. · DMW - Deutsche Medizinische Wochenschrift · 5
Similar Efficacy and Safety with LY2963016 Insulin Glargine Compared with Lantus Insulin Glargine in Patients with T1DM: The ELEMENT 1 Study
2014 · Thomas Blevins, Dominik Dahl, et al. · Canadian Journal of Diabetes · 4
Immunogenicity of the novel glucagon analog dasiglucagon: Results of a dedicated immunogenicity trial in type 1 diabetes
2021 · Thomas R. Pieber, Olubukola Ajala, et al. · Diabetes Technology & Therapeutics · 2
232-OR: Long-Term Safety and Efficacy of Ultra-Rapid Lispro (URLi) in PRONTO-T1D
2020 · LESLIE J. KLAFF, JANG IK CHO, et al. · Diabetes · 2
Works count: 41
Citation count: 2,044
H-index: 17
I10-index: 19
Year
Topic
Type